[1] |
Tarapore PE, Vassar MJ, Cooper S, et al. Establishing a traumatic brain injury program of care: benchmarking outcomes after institutional adoption of evidence-based guidelines[J]. J Neurotrauma, 2016, 33(22): 2026-2033.
|
[2] |
Majdan M, Rusnák M, Bražinová A, et al. Severity, causes and outcomes of traumatic brain injuries occurring at different locations: implications for prevention and public health[J]. Cent Eur J Public Health, 2015, 23(2): 142-148.
|
[3] |
刘盛明,苑玉清,侯敏, 等. 创伤性脑损伤脑组织NF-kB表达变化规律及PDTC对其影响[J]. 四川医学, 2013, 34(2): 167-169.
|
[4] |
Zusman BE, Kochanek PM, Jha RM. Cerebral edema in traumatic brain injury: a historical framework for current therapy[J]. Curr Treat Options Neurol, 2020, 22(3): 9.
|
[5] |
熊莉娜,熊枝繁,涂艳. 核转录因子-kB、表皮生长因子受体在食管鳞状细胞癌组织中的表达及意义[J]. 实用医学杂志, 2010, 26(16): 2941-2942.
|
[6] |
Fujimura M, Usuki F, Kawamura M, et al. Inhibition of the Rho/ROCK pathway prevents neuronal degeneration in vitro and in vivo following methylmercury exposure[J]. Toxicol Appl Pharmacol, 2011, 250(1): 1-9.
|
[7] |
Cheng R, Shao MY, Yang H, et al. The effect of lysophosphatidic acid and Rho-associated kinase patterning on adhesion of dental pulp cells[J]. Int Endod J, 2011, 44(1): 2-8.
|
[8] |
Haydont V, Bourgier C, Vozenin-Brotons MC. Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity[J]. Br J Radiol, 2007, 80(1): S32-S40.
|
[9] |
Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease[J]. Trends Pharmacol Sci, 2011, 32(3): 167-173.
|
[10] |
Hall A, Lalli G. Rho and ras GTPases in axon growth, guidance, and branching[J]. Cold Spring Harb Perspect Biol, 2010, 2(2): a001818.
|
[11] |
Bryan BA, Dennstedt E, Mitchell DC, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis[J]. FASEB J, 2010, 24(9): 3186-3195.
|
[12] |
Hu E, Lee D. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges[J]. Expert Opin Ther Targets, 2005, 9(4): 715-736.
|
[13] |
Cheng HL, Su SJ, Huang LW, et al. Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis - involvement of STAT3 and RhoA activation[J]. Mol Cancer, 2010, 9: 126.
|
[14] |
Goupil E, Tassy D, Bourguet C, et al. A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway[J]. J Biol Chem, 2010, 285(33): 25624-25636.
|
[15] |
Zhu L, Chen T, Chang X, et al. Salidroside ameliorates arthritis-induced brain cognition deficits by regulating Rho/ROCK/NF-κB pathway[J]. Neuropharmacology, 2016, 103: 134-142.
|
[16] |
Hao X, Yuan J, Dong H. Salidroside prevents diabetes-induced cognitive impairment via regulating the Rho pathway[J]. Mol Med Rep, 2019, 19(1): 678-684.
|
[17] |
Monceau V, Pasinetti N, Schupp C, et al. Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity[J]. Curr Drug Targets, 2010, 11(11): 1395-1404.
|
[18] |
Kogata N, Tribe RM, Fässler R, et al. Integrin-linked kinase controls vascular wall formation by negatively regulating Rho/ROCK-mediated vascular smooth muscle cell contraction[J]. Genes Dev, 2009, 23(19): 2278-2283.
|
[19] |
Tanimori Y, Tsubaki M, Yamazoe Y, et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway[J]. Clin Exp Metastasis, 2010, 27(7): 529-538.
|
[20] |
Arita R, Hata Y, Ishibashi T. ROCK as a therapeutic target of diabetic retinopathy[J]. J Ophthalmol, 2010, 2010: 175163.
|
[21] |
Li QY, Wo D, Huang Y, et al. Alkaloids from nelumbinis plumula (AFNP) ameliorate aortic remodeling via RhoA/ROCK pathway[J]. Biomed Pharmacother, 2019, 112: 108651.
|
[22] |
姜文文,毕伟康,李泽坤, 等. Nogo-OMgp/Rho-Rock信号通路在CO中毒急性脑损伤中的作用及盐酸法舒地尔治疗的可行性分析[J]. 中华神经医学杂志, 2020, 19(5): 439-448.
|